Echo faces a proxy challenge; InspireMD plans a field correction;

@FierceMedDev: The latest FierceDiagnostics is out, with scoops on Quest Diagnostics, Roche, VC funding and more. Read | Follow @FierceMedDev

@VarunSaxena2: Zogenix retaining rights to DosePro delivery technology in transaction with Endo. Story via FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: ICYMI here's yesterday's issue of FierceBiotech Research (stories on MERS, Alzheimer's and HIV). Read | Follow @EmilyWFierce

@MichaelGFierce: Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. More via FierceDrugDelivery | Follow @MichaelGFierce

> Facing a proxy challenge from investor Platinum Management, Echo Therapeutics ($ECTE) is entreating investors to re-elect its incumbent board director. News

> InspireMD ($NSPR) is warning customers that a problem with its MGuard Prime EPS devices could lead to stent dislodgment, and the company is planning a field modification of all affected products. More

Biotech News

@FierceBiotech: GSK ups odds on heart drug hopeful with a changeup in endpoints. Story | Follow @FierceBiotech

@JohnCFierce: So after years of watching U.K. R&D get carved up like a cooked goose, lawmakers now want to probe the Pfizer deal? More | Follow @JohnCFierce

@DamianFierce: This list, via @JacobEPVantage, is like looking at an old yearbook. Qnexa was cute. I don't even recognize Sovaldi. Report | Follow @DamianFierce

@EmilyMFierce: ICYMI here's yesterday's issue of FierceBiotech Research: Report | Follow @EmilyMFierce

> Biopsy snafu torpedoes PhII prostate cancer data for Nymox. More

> Sanofi's MS team rebuilds its case for the FDA-rejected MS drug Lemtrada. Story

> Regeneron R&D chief's compensation shrinks, but still tops the chart. Article

Pharma News

@FiercePharma: Sources: Bayer offers animal health biz, cash for Merck's OTC unit. News | Follow @FiercePharma

@TracyStaton: Allergan to propose to Shire again, but does Irish beauty want to get engaged? Story | Follow @TracyStaton

@EricPFierce: The FDA is letting Baxter import saline from a plant in Spain to help ease the shortage in the US. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Advair slide, China woes drop-kick Glaxo profits in Q1. Article | Follow @CarlyHFierce

> Stymied by Meda, deal-hungry Mylan could jump on Stada or Mallinckrodt. Story

> Regeneron chief outranks every other biopharma CEO with $36M in 2013 pay. More

> Sanofi takes a more subdued approach by unloading older products. Article

Drug Delivery News

> Zogenix retaining rights to DosePro delivery technology in transaction with Endo. News

> Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. Report

> Civitas announces positive results from Phase II inhaled levodopa trial. Story

> Cynapsus makes progress on sublingually delivered Parkinson's therapy. More

> Johns Hopkins team delivers cancer-killing DNA to mouse brains with nanovehicles. Article

> Imaging technique maps transdermal drug migration. Item

Diagnostics News

> Seattle firm attracts $47.25M for blood test that confirms benign lung nodules. News

> A certain protein marks tumors that will resist Astellas' prostate cancer drug Xtandi. Story

> Two new osteoarthritis biomarkers eyed for predictive Dx. More

> Quest to unveil new epilepsy tests in the wake of disappointing Q1 numbers. Article

> Roche-Evotec biomarker collaboration scores its first big milestone. Story

Pharma Marketing News

> Merck recruits ex-Law & Order star for new diabetes campaign. News

> With Big Pharma mergers in the works, whose SG&A costs look ripe for cutting? Report

> Sanofi bucks unit-sale trend with plan to unload $7B worth of older products. Item

> It's make-or-break time for GSK's new sales model as Anoro hits the U.S. market. Story

> GlaxoSmithKline dispatches sales and marketing team to clean up in China. More

> Simplify the DTC roll call of side effects? Yes, please, drugmakers tell FDA. Article